Profile data is unavailable for this security.
About the company
Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
- Revenue in SEK (TTM)1.59bn
- Net income in SEK223.25m
- Incorporated2004
- Employees228.00
- LocationCamurus ABIdeongatan 1ALUND 223 62SwedenSWE
- Phone+46 462865730
- Fax+46 462865739
- Websitehttps://www.camurus.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Swedencare AB (publ) | 2.47bn | 76.20m | 7.37bn | 559.00 | 96.70 | 0.9593 | 18.87 | 2.98 | 0.4801 | 0.4801 | 15.58 | 48.39 | 0.2428 | 2.26 | 8.69 | 5,087,037.00 | 0.7483 | 1.38 | 0.7727 | 1.43 | 56.76 | 55.34 | 3.08 | 5.10 | 1.67 | 2.42 | 0.1726 | 45.33 | 27.48 | 88.16 | -37.96 | 20.24 | 30.90 | -- |
| BioGaia AB | 1.36bn | 336.82m | 10.56bn | 222.00 | 32.51 | 6.77 | 25.89 | 7.79 | 3.33 | 3.33 | 13.42 | 16.01 | 0.6442 | -- | -- | 6,455,538.00 | 16.00 | 15.47 | 17.73 | 16.93 | 73.59 | 73.30 | 24.85 | 27.70 | -- | -- | 0.00 | 104.42 | 17.44 | 11.81 | -2.25 | 11.20 | 29.27 | 28.10 |
| Bonesupport Holding AB | 814.46m | 90.58m | 21.69bn | 131.00 | 241.89 | 33.22 | 214.53 | 26.63 | 1.36 | 1.36 | 12.29 | 9.92 | 1.16 | 0.6138 | 5.62 | 7,756,762.00 | 12.85 | -9.08 | 14.98 | -11.28 | 92.43 | 90.25 | 11.12 | -11.65 | 3.50 | -- | 0.0222 | -- | 79.76 | 43.65 | 459.44 | -- | 18.39 | -- |
| Vimian Group AB | 4.11bn | 2.98m | 23.16bn | 1.10k | 8,924.75 | 3.00 | 57.94 | 5.64 | 0.005 | 0.005 | 8.37 | 14.89 | 0.3401 | 2.85 | 6.75 | 3,733,535.00 | 0.0938 | -- | 0.1025 | -- | 46.88 | -- | 0.2758 | -- | 2.18 | 2.06 | 0.2734 | -- | 17.92 | -- | 245.95 | -- | -- | -- |
| Bavarian Nordic A/S | 9.51bn | 1.11bn | 26.40bn | 1.38k | 23.64 | 1.60 | 12.94 | 2.77 | 9.06 | 9.06 | 78.44 | 133.68 | 0.4157 | 1.50 | 5.10 | 4,410,899.00 | 4.83 | 1.21 | 6.24 | 1.48 | 56.91 | 53.72 | 11.63 | 4.06 | 0.9311 | -- | 0.0118 | 0.00 | 124.14 | 69.78 | 524.66 | -- | 35.76 | -- |
| Camurus AB | 1.59bn | 223.25m | 35.14bn | 228.00 | 157.53 | 11.96 | 147.61 | 22.05 | 3.79 | 3.79 | 27.51 | 49.94 | 0.6122 | 1.09 | 4.86 | 7,480,770.00 | 8.58 | -1.13 | 10.10 | -1.41 | 92.01 | 90.05 | 14.01 | -1.63 | 7.11 | -- | 0.0071 | -- | 79.52 | 103.39 | 676.63 | -- | 16.29 | -- |
| ALK-Abello A/S | 8.10bn | 1.08bn | 51.23bn | 2.81k | 52.29 | 7.28 | 32.95 | 6.32 | 3.09 | 3.09 | 22.91 | 22.22 | 0.7673 | 1.27 | 6.11 | 1,834,278.00 | 10.22 | 3.50 | 12.56 | 4.37 | 63.42 | 60.66 | 13.32 | 5.07 | 1.29 | 479.50 | 0.0934 | 0.00 | 6.94 | 10.60 | 45.07 | -- | 16.32 | -- |
| Orion Oyj | 16.67bn | 3.87bn | 74.19bn | 3.82k | 19.13 | 6.85 | 16.25 | 4.45 | 2.36 | 2.36 | 10.16 | 6.58 | 0.9593 | 1.53 | 6.94 | 393,502.20 | 22.25 | 19.47 | 28.25 | 24.16 | 59.89 | 59.38 | 23.19 | 20.71 | 1.41 | 143.69 | 0.2174 | 91.83 | -11.26 | 4.01 | -37.97 | 1.89 | 11.82 | 1.55 |
| Swedish Orphan Biovitrum AB (publ) | 25.44bn | 3.51bn | 119.33bn | 1.81k | 33.33 | 3.10 | 16.58 | 4.69 | 10.06 | 10.06 | 72.98 | 108.01 | 0.3443 | 1.37 | 5.72 | 14,353,840.00 | 4.75 | 5.93 | 5.85 | 7.60 | 78.60 | 77.42 | 13.81 | 16.61 | 0.6225 | 4.35 | 0.325 | 0.00 | 17.74 | 19.34 | -8.68 | -0.0729 | 53.61 | -- |
Data as of Nov 05 2024. Currency figures normalised to Camurus AB's reporting currency: Swedish Krona SEK
18.09%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 31 May 2024 | 2.61m | 4.45% |
| Swedbank Robur Fonder ABas of 30 Sep 2024 | 1.95m | 3.33% |
| Handelsbanken Fonder ABas of 30 Sep 2024 | 1.42m | 2.42% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 1.14m | 1.95% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 700.35k | 1.19% |
| SEB Investment Management ABas of 30 Sep 2024 | 625.22k | 1.07% |
| AFA Sjukf�rs�kringsaktiebolag (Invt Mgmt)as of 31 May 2024 | 614.29k | 1.05% |
| Devon Equity Management Ltd.as of 31 Oct 2024 | 609.48k | 1.04% |
| Baillie Gifford & Co.as of 30 Sep 2024 | 484.98k | 0.83% |
| JPMorgan Asset Management (UK) Ltd.as of 30 Sep 2024 | 447.85k | 0.76% |
More ▼
Data from 30 Jun 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
